Reimbursement
CMS IDE Coverage (Category A & B)
In one line
Medicare coverage framework for items and services furnished in FDA-approved IDE studies — Category A (experimental) and Category B (non-experimental).
Definition
Under 42 CFR 405 Subpart B, CMS may cover routine costs and, for Category B IDEs, the device itself when furnished in an FDA-approved investigational device exemption study. FDA classifies an IDE device as Category A (experimental, novel risk-benefit profile not yet established) or Category B (non-experimental, generally a follow-on or substantial-equivalent design). Category B devices may be covered by Medicare; Category A devices generally are not, though routine costs may still be covered under the Clinical Trial Policy NCD 310.1.
Why it matters
IDE coverage decisions can dramatically alter trial economics — a Category B classification with CMS coverage approval converts trial-device costs from sponsor-borne to payer-reimbursed.
Common pitfalls
- •Assuming Category B classification automatically yields Medicare coverage — sites must still seek CMS approval and meet routine-cost criteria.
- •Failing to coordinate FDA IDE submission with the CMS coverage submission early.
Sources